The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO with Entera’s proprietary N-Tab™ technology for patients suffering from short bowel syndrome and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback